MediWound Announces Publication of the EscharEx Phase II ChronEx Study Results for Venous Leg Ulcers
| MDWD Stock | USD 16.90 0.43 2.48% |
About 61% of Mediwound's investor base is looking to short. The analysis of overall sentiment of trading Mediwound stock suggests that many investors are alarmed at this time. The current market sentiment, together with Mediwound's historical and current headlines, can help investors time the market. In addition, many technical investors use Mediwound stock news signals to limit their universe of possible portfolio assets.
Mediwound |
Research Published in THE LANCETs eClinicalMedicineEscharEx Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 -- MediWound Ltd. , the global leader in next-generation enzymatic therapeutics for tissue repair, today announces the peer-reviewed publication on the Phase II ChronEx study assessing the safety and efficacy of EscharEx for the treatment of Venous Leg Ulcers in the pres
Read at finance.yahoo.com
 |
Mediwound Fundamental Analysis
We analyze Mediwound's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mediwound using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mediwound based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Mediwound is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Mediwound Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Mediwound stock to make a market-neutral strategy. Peer analysis of Mediwound could also be used in its relative valuation, which is a method of valuing Mediwound by comparing valuation metrics with similar companies.
Peers
Mediwound Related Equities
| CTMX | CytomX Therapeutics | 6.25 | ||||
| ASMB | Assembly Biosciences | 2.63 | ||||
| SLNO | Soleno Therapeutics | 1.96 | ||||
| CAPR | Capricor Therapeutics | 1.28 | ||||
| CRNX | Crinetics Pharmaceuticals | 1.21 | ||||
| ACHL | Achilles Therapeutics | 0.94 | ||||
| MBRX | Moleculin Biotech | 1.13 | ||||
| BPTH | Bio Path | 2.44 | ||||
| TIL | Instil Bio | 2.83 |
Complementary Tools for Mediwound Stock analysis
When running Mediwound's price analysis, check to measure Mediwound's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mediwound is operating at the current time. Most of Mediwound's value examination focuses on studying past and present price action to predict the probability of Mediwound's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mediwound's price. Additionally, you may evaluate how the addition of Mediwound to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |